Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €36.14 EUR
Change Today +0.147 / 0.41%
Volume 157.1K
SAZ On Other Exchanges
As of 12:56 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (SAZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/15 - €36.48
52 Week Low
12/17/14 - €24.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STADA ARZNEIMITTEL AG (SAZ)

Related News

No related news articles were found.

stada arzneimittel ag (SAZ) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (SAZ) Details

STADA Arzneimittel AG engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s principal products include Omeprazole, a stomach medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Atorvastatin, an antilipemic; and Phospholipide, a liver medicine. The Branded Products segment offers non-prescription products. This segment primarily provides APO-go, a Parkinson medicine; Aqualor, a cold medicine based on seawater; Grippostad, a cold medicine; Snup, a nasal preparation; and Ladival, a sunscreen product. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.

10,447 Employees
Last Reported Date: 10/30/15
Founded in 1895

stada arzneimittel ag (SAZ) Top Compensated Officers

Chairman of The Executive Board
Total Annual Compensation: €2.8M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.1M
Chief Business Development & Central Services...
Total Annual Compensation: €1.1M
Compensation as of Fiscal Year 2014.

stada arzneimittel ag (SAZ) Key Developments

STADA Arzneimittel AG Announces Group Earnings Results for the Nine Months of 2015; Confirms earnings Guidance for the Full Year 2015

STADA Arzneimittel AG announced group earnings results for the nine months of 2015. For the nine months, the company reported group sales of EUR 1,533.5 million against EUR 1,482.7 million a year ago. EBITDA, reported was EUR 281.2 million against EUR 293.6 million a year ago. EBITDA adjusted was EUR 293.8 million against EUR 316.2 million a year ago. Net income, reported was EUR 89.9 million against EUR 99.1 million a year ago. Net income, adjusted was EUR 126.9 million against EUR 136.1 million a year ago. Earnings per share, reported were EUR 1.46 against EUR 1.64 a year ago. Earnings per share, adjusted were EUR 2.07 against EUR 2.25 a year ago. Both reported key earnings figures and adjusted key earnings figures recorded a decrease in the reporting period. This development was primarily attributable to negative currency effects from the considerable weakness of the RUB as well as the strong devaluation of UAH and KZT. Reported operating profit decreased in the reporting period by 3% to EUR 179.8 million against EUR 185.5 million a year ago. After adjusting the key earnings figures for influences distorting the period comparison resulting from one-time special effects, adjusted operating profit decreased by 6% in the first nine months of 2015 to EUR 217.8 million against EUR 232.6 million a year ago. Cash flow from operating activities amounted to EUR 137.7 million in the first three quarters of 2015 against EUR 123.8 million a year ago. Free cash flow was at EUR 10.6 million against negative free cash flow of EUR 62.9 million a year ago. Free cash flow adjusted for payments for significant investments or acquisitions and proceeds from significant disposals amounted to EUR 68.6 million against EUR 75.6 million a year ago. Adjusted group sales showed an increase of 6%, with portfolio effect accounting for plus 1.5% and currency effects for minus 3.7%. The company confirmed earnings guidance for the full year 2015. In the current financial year, the group has been confronted with very difficult framework conditions, especially due to the ongoing CIS crisis. In light of this, for the outlook for 2015, the company expects to be able to achieve slight growth in group sales adjusted for currency and portfolio effects. Due to the development of the RUB and increased risks in connection with consumer mood and the general market situation, however, it anticipates a decreased earnings contribution from Russia. Taking these developments into account and based on currency relations at the time the preliminary outlook was published, the company expects a substantial decrease in adjusted EBITDA and adjusted net income. The company expects the ratio of net debt excluding further acquisitions to adjusted EBITDA to be at a level of nearly 3 in 2015. The company assumes a good fourth quarter of 2015. And therefore, the company expects that it's going to be an opportunity for 2015 to have adjusted net income of EUR 160 million to EUR 170 million.

Stada-Arzneimittel AG, Q3 2015 Earnings Call, Nov 12, 2015

Stada-Arzneimittel AG, Q3 2015 Earnings Call, Nov 12, 2015

Stada-Arzneimittel AG Reports Earnings Results for the Second Quarter Ended June 30, 2015

Stada-Arzneimittel AG reported earnings results for the second quarter ended June 30, 2015. The company has reported that earnings after taxes distributable to shareholders for the second quarter ended June 30, 2015 were EUR 32.41 million, or EUR 0.53 per diluted share, compared to EUR 31.77 million, or EUR 0.52 per diluted share, for the same quarter ended June 30, 2014. Sales for the second quarter ended June 30, 2015 were EUR 539.71 million, compared to EUR 495.37 million for the same quarter ended June 30, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAZ:GR €36.14 EUR +0.147

SAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 3,099 INR -1.45
Endo International PLC $62.33 USD +1.33
Impax Laboratories Inc $44.57 USD -0.15
Merck KGaA €96.27 EUR +0.02
Medicines Co/The $42.60 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation SAZ Industry Range
Price/Earnings 37.9x
Price/Sales 1.0x
Price/Book 2.2x
Price/Cash Flow 38.3x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact STADA ARZNEIMITTEL AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at